Richard Carroll joins HistoRx
This article was originally published in Clinica
Tissue-based diagnostics firm HistoRx has appointed Richard Carroll to the newly created position of vice-president of clinical research. Before joining HistoRx (New Haven, Connecticut), Dr Carroll was in a similar role at Cascade Medical Enterprises, a privately-held diagnostics company. Previously, he worked for other firms including Becton Dickinson and Visible Genetics, which was later acquired by Siemens Healthcare Diagnostics. HistoRx’s diagnostic products and services are based on its AQUA tissue biomarker analysis technology, which it hopes will replace immunohistochemistry.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.